GW Pharmaceuticals plc, the company developing a portfolio of non-smoked cannabis-based prescription medicines, is today announcing preliminary results from its first four completed Phase III clinical... more
GW Pharmaceuticals plc, the pharmaceutical company developing a portfolio of non-smoked cannabis-based prescription medicines, announces the latest Phase II data from a completed 34 patient study in p... more
Dr Geoffrey Guy, Executive Chairman of GW Pharmaceuticals, said: "Progress across the breadth of the Group's activities has continued according to expectation in the first half of the financial year a... more
GW Pharmaceuticals plc, the company developing a portfolio of non-smoked, cannabis-based prescription medicines, announces the commencement of Phase Three clinical trials in four new indications.... more
GW Pharmaceuticals plc has welcomed the Government's statement that it will ask the National Institute for Clinical Excellence (NICE) to examine the possible provision of the Company's medicines by th... more
... more
GW Pharmaceuticals plc, the pharmaceutical company developing a portfolio of non-smoked cannabis-based prescription medicines, announces its first set of preliminary results since flotation on the Alt... more
GW Pharmaceuticals plc, the company developing a portfolio of non-smoked cannabis-based prescription medicines, announces that it has expanded its Phase Three clinical trials programme into cancer pai... more
